Mesenchymal stromal cells (MSCs) possess unique immunomodulatory features. MSCs dampen effector T-cell response while promoting the emergence of regulatory T cells. By skewing this balance, MSC could represent the ideal strategy for tolerance induction in organ transplantation. Here we review recent evidence on the efficacy of MSC-based therapy in experimental models of solid organ transplantation as well as the early clinical experiences in kidney transplantation.
INTRODUCTION
Since the first successful renal transplantation in Boston in 1954 [1] , organ transplantation has made dramatic strides, evolving from an experimental procedure to standard of care in the treatment of patients with end-stage organ disease. Although powerful immunosuppressive drugs are undoubtedly the cornerstone of transplant success by preventing acute cellular rejection [2] , they affect the function of all responding T cells irrespective of their antigen-specificity, rendering transplant recipients susceptible to life-threatening infections and malignancy [3, 4] . In addition, life-long use of broad-spectrum pharmacological immunosuppression is associated with unwanted side effects, including accelerated cardiovascular disease, metabolic complications and with a direct toxic effect to transplanted tissues [3, 4] , eventually contributing to long-term graft loss, a common event in renal transplantation. Ideally, the induction of donorspecific tolerance would overcome these shortcomings, possibly allowing indefinite graft survival [5] .
The immune system has evolved multiple mechanisms for controlling the effector adaptive immune response [6] . Transplantation of a major histocompatibility complex-incompatible graft triggers the activation of graft destructive effector T cells as well as protective regulatory T cells (Tregs); it is the balance of such opposing subsets that ultimately determines the fate of the allotransplant [5] . The most extensively studied populations of Tregs are the so-called naturally occurring CD4
þ CD25 þ Foxp3 þ Treg that develop in the thymus [7, 8] and the adaptive Tregs that are induced in the periphery in response to antigen stimulation under tolerogenic conditions [9] . Together, Tregs maintain tolerance to self-antigens and control excessive immune response to foreign antigens and may contribute to the induction and maintenance of tolerance to allografts [10, 11] .
Bone marrow-derived multipotent mesenchymal stromal cells (MSC) have emerged as a promising cell population for immunomodulatory therapy in transplantation given their unique immunoregulatory properties on both the adaptive [12] and innate [13 && ] immune cells. MSC are capable of suppressing T effector cells [14] including memory T cells [15, 16] , skewing T cells toward Foxp3 þ Tregs with concurrent suppression of Th1, Th2 or Th17 responses [14] . The findings that MSC target effector/memory T cells and promote the development of Tregs have led to propose MSC as a novel, potentially suitable cell-based approach for tolerance induction in organ transplantation.
Here, we have reviewed recent evidence on the capability of MSC to skew the balance between T effector cells and Tregs as well as the safety and efficacy of MSC-based therapy in experimental models of solid organ transplantation and in early clinical experience.
MESENCHYMAL STROMAL CELLS AND REGULATORY T CELL GENERATION
MSC are a heterogeneous population of adult, fibroblast-like multipotent cells characterized by their ability to differentiate into tissues of mesodermal lineages, including adipocytes, chondrocytes and osteocytes [17] . First identified and isolated from the bone marrow as plastic adherent cells [18] , MSC are now isolated from a number of other sources including umbilical cord blood, adipose tissue and muscle [19, 20] . The isolation of MSC by in-vitro expansion of plastic-adherent cells yields a heterogeneous cell population evidenced by the different morphology and functional potential. In order to create a consensus and more uniformly characterize these cells the International Society of Cellular Therapy proposed a standard set to define the identity of MSC [21] : adherence to plastic surfaces; potential to differentiate into osteocytes, adipocytes and chondrocytes under standard invitro differentiating conditions; and expression of CD105, CD73 and CD90 and must lack expression of CD45, CD34, CD14, CD11b, CD79a and HLA-DR.
Several in-vitro and in-vivo studies have documented the remarkable ability of MSC to polarize T cells toward a regulatory phenotype. In-vitro coincubation of human MSC with peripheral blood mononuclear cells or with purified CD4 þ T cells induced the differentiation of CD4 þ T cells into Foxp3-expressing Tregs [22] [23] [24] [25] , a process involving direct MSC contact with T cells followed by prostaglandin E 2 and transforming growth factor b-1 (TGFb-1) expression [22, 24] . Expanded Tregs potently suppressed the alloantigen-specific proliferative response in mixed-lymphocyte reaction (MLR) assay [23, 24] . MSC induced a Treg phenotype (CD25 bright Foxp3 þ CD127 low ) both in naive CD3 þ CD45RA þ and in memory CD3 þ CD45RO þ T cells [26] . Other potential mechanisms of MSC-induced Treg generation include the release of soluble HLA-G5, a nonclassical HLA class I molecule [27] or of microvescicles [28] . MSC are also able to reprogram fully differentiated Th17 cells into Foxp3-expressing Tregs [29] ]. Indeed, systemic infusion of either syngeneic or allogeneic murine bone marrow MSC in these mice-induced transient T-cell apoptosis via the FasL-Fas pathway, which triggered macrophages to produce high levels of TGFb in the peripheral blood, eventually enhancing CD4
This effect translated into the amelioration of the disease phenotypes [36 && ]. The polarization of T cells toward a Treg phenotype with a concomitant decrease in Th1/Th17 development has been also shown to be associated with MSC immunomodulatory effect in other experimental models of autoimmune and inflammatory diseases such as systemic lupus erythematosus [37] , collagen-induced arthritis [38] [39] [40] , diabetes [41] [42] [43] [44] , colitis [45] and autoimmune myasthenia gravis [46, 47] .
Together these in-vitro and in-vivo studies indicate the ability of MSC to modulate the immune response to antigens mainly by promoting the generation of T cells with regulatory phenotype and possibly lowering the availability of Th1/Th17 effector cells.
MESENCHYMAL STROMAL CELLS IN EXPERIMENTAL MODELS OF SOLID ORGAN TRANSPLANTATION
Almost a decade has elapsed since the first study reporting the capability of MSC to prolong survival of skin graft in nonhuman primates [48] . Subsequent studies in rodent models of heart [49] [50] [51] [52] [53] [54] [55] , liver [56] ] and graft-versus-host disease [70] , supporting the concept that MSC need to interact with immune cells in sites of initial effector T-cell priming in order to effectively exert immunomodulation.
Most of the experimental studies with MSC in organ transplantation have been performed without any additional pharmacological immunosuppressive therapy. However, in the perspective of translating cell-based MSC therapy to clinical transplant programs, it is critical to evaluate the possible negative impact of currently used antirejection drugs on MSC-induced Treg generation and function and eventually graft survival.
Data on the effect of cyclosporine (CsA) on MSC-induced immunoregulation are controversial [55, 66] (Table 1) . There is experimental and clinical evidence that calcineurin inhibitors (CNI), by blocking IL-2 expression in T cells, prevent both Treg development and homeostasis [71] , although at low-dose these drugs may expand Tregs in both the periphery and the allografts [72] .
In a mouse model of in-vivo MLR, CsA inhibited the MSC-mediated suppression of CD4 þ T-cell proliferation [54] . At variance, other in-vitro studies have documented the CsA did not interfere with MSC-mediated Treg generation [23] and that MSC Heart tx in rats Heart tx in rats Heart-lung tx in rats synergized with CsA in inhibiting T lymphocyte activity [73] . [74] . In an experimental model of heart transplantation in mice rapamycin synergized with MSC in inducing Treg-mediated tolerance [53] . Similarly, in the same model in rats, mycophenolate combined with donor MSC induced long-term graft acceptance [51, 54] .
Altogether these results indicate that in experimental models MSC infusion synergized with low-dose or transient immunosuppressive drug treatment in inducing long-term graft acceptance, indicating that these cells allow safe minimization of maintenance pharmacological antirejection therapy.
MESENCHYMAL STROMAL CELLS IN KIDNEY TRANSPLANTATION IN HUMANS
There are few protocols of MSC-based therapy in organ transplantation (www.clinicaltrials.gov). Actually, clinical trials on the use of MSC in kidney and liver transplantation are being performed in our center in Bergamo, Italy (NCT00752479), in Leiden, The Netherlands (NCT00734396), in Liege, Belgium (NCT01429038) and in China (NCT00659620). So far only results from the Italian and Chinese experiences with MSC in living-donor kidney transplant recipients have been published. Our protocol is aimed at characterizing the safety and tolerability of peritransplant MSC infusion and to verify whether MSC, by skewing Treg/Teff balance allow creating a protolerogenic environment. We initially started with two living-related donor kidney recipients who were given ex-vivo expanded, autologous, bone marrow-derived MSC at day 7 posttransplant, after induction therapy with basiliximab/low-dose thymoglobulin [75 & ]. MSC infusion did promote on long-term a protolerogenic environment characterized by lower memory/effector CD8 þ T cells, expansion of CD4 þ Tregs and reduction of donorspecific CD8 þ T-cell cytotoxicity, compared with control kidney transplant recipients given the same induction therapy but not MSC. However, few days after cell infusion, both MSC-treated patients developed acute renal insufficiency. Histological and immunohistochemical analysis of graft infiltrating cells did exclude an acute cellular or humoral rejection, but intragraft recruitment of neutrophils together with MSC, as well as complement-C3 deposition were observed [75 & ]. It was hypothesized that the subclinical inflammatory environment of the graft in the few days postsurgery could have favoured the prevalent intragraft recruitment and activation of the infused MSC promoting a proinflammatory milieu with eventual acute renal dysfunction (engraftment syndrome), as reported by others with combined kidney and bone marrow transplantation [76] . This hypothesis has been confirmed back into a murine kidney transplant model showing that MSC administration before (day-1) but not few days after kidney transplantation avoided the acute deterioration of graft function, while maintaining the immunomodulatory effect of MSC [63 & ]. The Chinese group performed a single-site prospective, randomized study aimed at comparing the risk-benefit profile of bone marrow-derived autologous MSC infusion (at kidney reperfusion and 2 weeks later) versus induction therapy with the anti-IL-2 receptor antibody basiliximab in living-related donor kidney transplants [77 & ]. MSC treatment resulted in lower incidence of acute rejection at 6 months posttransplant, decreased risk of opportunistic infection and better estimated renal function. The investigators concluded that MSC may replace basiliximab induction therapy, allowing the use of lower than conventional CNI maintenance doses without compromising patient safety and graft outcome. However, lower acute rejection rate and better renal function documented at 6 months after transplantation were transient and not confirmed at 1 year. The study has been criticized in a recent letter [78] . Unfortunately, this study did not report any attempt to in-depth assess the in-vivo effects of MSC on host immune system, especially on Treg and effector T-cell function by any immunological tests, which are mandatory for an innovative cell therapy still in its infancy before moving it to routine clinical application for transplant programs.
CONCLUSION
Cell therapy with MSC in solid organ transplantation has undoubtedly a great potential. However, although initial preclinical and early clinical results appear promising, moving the concept of MSCbased therapy forward toward clinical application should be critically assessed. We have to be aware that, so far, our knowledge about MSC is too scarce for embarking in large clinical trials and there remain many open questions both on the risk and the real benefit of these cells. Further studies are needed to establish how and where these cells have to be administered and how they may function to modulate host immune response in vivo in clinical transplant setting.
Rather than studying thousands of patients without enough attempt to safety issues and mechanistic/immunomodulatory pathways it seems preferable in our opinion in this kind of studies to proceed in few patients, however, very intensively investigated. Issues like source, dose, timing of administration, in-vivo localization, interaction with immunosuppressive drugs, whether these cells have to be used for prevention of acute rejection or for tolerance induction have not been addressed in this field and more explorative studies are required before embarking in formal clinical trials. This study shows that in a murine kidney transplant model, posttransplant MSC infusion causes premature graft dysfunction and fails to prolong graft survival, whereas pretransplant MSC infusion induces a significant prolongation of kidney graft survival by a regulatory T-cell dependent mechanism. 64.
